If this pivotal preclinical study pans out, we'll try to move into human clinical trials as soon as feasible," Marshall said...and a 2.5-year warrant to buy up to about 3.5 million shares of common stock at an exercise price of $1.18 per share...Rodman & Renshaw LLC acted as exclusive placement agent.

ArQule Inc., of Woburn, Mass., plans to sell 6 million shares of common stock in an underwritten public offering, which would bring in about $49 million based on Monday's closing price...Proceeds will be used for clinical trials, such as the Phase III trials of tivantinib in lung cancer, and for general corporate purposes

The company is splitting the cost of ocriplasmin's clinical development in additional indications, including age-related macular degeneration and diabetic retinopathy, on a 50/50 basis with Alcon...Each unit consists of one share of common stock and a warrant to purchase one share

The condition can vary in severity and has easily assessed markers of clinical benefit...Net proceeds totaling about $7.2 million will be used for general corporate purposes, including clinical trial expenses and R&D expenses...The funds will be used to develop PRX 302, a candidate for benign prostatic hyperplasia.

The shares will be converted into common stock immediately prior to the IPO's closing...The securities are subject to a four-month holding period.

It will use proceeds of approximately $86 million to complete clinical development of dalbavancin, to fund commercialization activities for the product in the U.S...Durata had 500,000 shares of common stock outstanding on Feb. 29, and 77,197,936 additional shares issuable upon automatic conversion of all series A preferred stock

Holders of the biotech's common stock and Series A warrants will be eligible to purchase one unit for each share of stock owned or issuable, with each unit consisting of one-half of a common share and a warrant to purchase an additional one-quarter of a common share...Proceeds will support clinical trials of cancer metabolism programs ME-344 and ME-143

Celldex Therapeutics Inc., of Needham, Mass., said underwriters of its public offering of common stock exercised in full their overallotment option to purchase an additional 1,575 million shares at $3.85 each...Celldex expects to use net proceeds from the offering, including the overallotment option, to fund clinical trials of its product candidates and for other corporate purposes

We're looking at the prevention of all the clinical signs associated with sickle cell disease – primarily the frequency of pain crises in these patients," Longenecker told BioWorld Today...The company issued Series G convertible preferred stock, without warrants, convertible into common stock at 40 cents per share

Those shares are convertible into common stock after March 8, 2017, at a rate of 1,000 common shares for one preferred share...Funds are expected to support ongoing business development and clinical efforts and for general corporate purposes

The data were presented last month at the 2012 American Society for Clinical Oncology Genitourinary Cancers Symposium...Enrollment in the Phase II portion of the study is complete, Heyman added, and clinical data are expected later this year...On Monday, the company's shares (OTCQB:ELTP) closed unchanged, at 10 cents.

LLC exercise their full overallotment option – are expected to support ongoing clinical development, particularly work on Amigal (migalastat HCl), which is in Phase III testing as a monotherapy for Fabry disease and in Phase II trials in combination with enzyme replacement therapy (ERT...TG Therapeutics Inc., of New York, said it closed a $25 million financing, with proceeds primarily going to support clinical development of ublituximab, a third-generation chimeric monoclonal antibody licensed from

Horizon Pharma Inc., of Deerfield, Ill., is bringing in $50.8 million in a private placement of about 14 million units – each comprising one share of common stock and a warrant to purchase 0.25 shares – priced at $3.62125 apiece...Proceeds are expected to fund R&D costs for the firm's Cell Pouch System, including the upcoming first clinical trial in diabetics receiving an islet transplant...Funds will be used to support ongoing drug development activities and for general corporate purposes and working

Cempra Inc., of Chapel Hill, N.C., said underwriters of its initial public offering exercised in full their option to purchase an additional 1.26 million shares of common stock at $6 per share, closing the overallotment on Feb. 27 and netting the company about $54.7 million from the offering...The company said the funds will allow it to complete clinical development of two late-stage programs in bone cancer and pancreatic cancer through the new drug applications

Serendipitously, independent clinical studies of the antecedent biomarkers of AD seem to have corroborated Satori's approach, he added...Currently, DARA has 7 million shares of common stock outstanding

The magnet used is relatively small, only one-fifteenth the field strength of a typical clinical MRI...Access Pharmaceuticals Inc., of Dallas, filed an S-1 with the SEC seeking to raise $10 million through a registered public offering of common stock and warrants...and Summer Street Research Partners acted as joint book-running managers.

Alexza Pharmaceuticals Inc., of Mountain View, Calif., said it priced a $22 million public offering, selling 44 million shares of common stock at 50 cents apiece, a 29 percent discount to Thursday's closing price...Funds are expected to allow the firm to start a planned clinical study of its Cell Pouch product in diabetic patients receiving islet cell transplantation

Proceeds will support clinical trials for product candidates, including Fabry disease therapeutic PRX-102...The CRL requested additional clinical trial data and information about chemistry, manufacturing and controls, testing specifications and assay validation...Halozyme Therapeutics Inc., of San Diego, completed its public offering of 7.8 million shares of common stock, including about 1 million shares sold to cover overallotments, priced at $10.61 each

common stock, and the merged company is now quoted on the OTCQB under the symbol "ONVO...The specialty pharma firm also improved its interest terms.